News
The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.
Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...
The health insurer has suffered mounting problems and backlash since the fatal shooting of former CEO Brian Thompson.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback